Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.

Also called NCT05761444

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 137 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05761444
Other papers using this trial's data
  • The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease BMC cardiovascular disorders, 2026-02-11 DOI, PubMed 41673582, PMC12998120 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05761444. Randomized; no masking; primary purpose treatment. Start 2023-07-26 (actual); primary completion 2024-09-04 (actual). Results posted on 2025-09-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
Acronym
BETTER
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Atozet 10/40 mg or 10/80 mg
Intervention (Drug)
Lipitor 40 mg or 80 mg
Lead sponsor
Organon and Co (class: industry)
Collaborator
IQVIA Pty Ltd (class: industry)

Record details

Record id
cardio:ct-nct05761444
Content hash
17d846d9453e4c7c556d56d1a521508091b9d1352a9e098db22052947a50305c